CYTX Cytori Therapeutics Inc

0.39
-0.02  -5%
Previous Close 0.41
Open 0.42
Price To book 1.22
Market Cap 13539364
Shares 34,716,318
Volume 501,722
Short Ratio 3.06
Av. Daily Volume 809,080

SEC filingsSee all SEC filings

  1. 8-K - Current report 171095943
  2. 8-K - Current report 171076903
  3. 8-K - Current report 171067196
  4. CT ORDER - Confidential treatment order 171044831
  5. S-1 - General form for registration of securities under the Securities Act of 1933 171031451

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced mid-January 2016 that first patients have been enrolled
Cytori Cell Therapy
Crohn’s Disease
Pivotal trial data released June 24, 2017 - endpoints not met.
ECCS-50
Scleroderma
Phase 2 interim data released February 2016 noted that the pre-specified primary endpoint did not obtain statistical significance. Full data due 3Q 2016
ECCO-50 cellular therapeutic
Osteoarthritis of the knee
Enrolling
Cell Enriched Adipose
Early stage female and male pattern hair loss

Latest News

  1. ETFs with exposure to Cytori Therapeutics, Inc. : September 7, 2017
  2. Cytori Announces Corporate Restructuring & Cost Reduction Plan
  3. ETFs with exposure to Cytori Therapeutics, Inc. : August 25, 2017
  4. Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment
  5. Edited Transcript of CYTX earnings conference call or presentation 10-Aug-17 9:30pm GMT
  6. Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
  7. Cytori reports 2Q loss
  8. Investor Network: Cytori Therapeutics, Inc. to Host Earnings Call
  9. Cytori Reports Second Quarter 2017 Business and Financial Results
  10. Cytori to Webcast Second Quarter Financial Results on August 10
  11. Cytori Therapeutics Announces Inducement Grants for New Employees
  12. Today's Research Reports on Stocks to Watch: Cytori Therapeutics and Novavax
  13. Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR)
  14. Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma
  15. American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy
  16. Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock?
  17. Cytori Receives Key Cell Therapy Patent for Scleroderma
  18. ETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017

SEC Filings

  1. 8-K - Current report 171095943
  2. 8-K - Current report 171076903
  3. 8-K - Current report 171067196
  4. CT ORDER - Confidential treatment order 171044831
  5. S-1 - General form for registration of securities under the Securities Act of 1933 171031451
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171026038
  7. 8-K - Current report 171021821
  8. 8-K - Current report 17977561
  9. 8-K/A [Amend] - Current report 17916775
  10. SD - 17881543